TransCode Therapeutics reported positive Phase 1a clinical data for its anti-miR-10b candidate TTX-MC138 in advanced solid tumors, with a 71.4% stable disease rate and notable durability. The promising early anti-tumor results support continued development of the RNA therapeutic.